Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Pazdur

Showing results (121-130 of 151) with videos related to

Pageof 16
Sort By:
Journal of the National Cancer Institute|December 12, 1992
Phase I trial of Taxotere: five-day scheduleR Pazdur, R A Newman, B M Newman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2019
Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancerG M Blumenthal, Y Gong, K Kehl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1994
Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinomaR Pazdur, Y Lassere, L T Soh, et al.
American Journal of Clinical Oncology|December 1, 1992
Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancerK P Hubbard, R Pazdur, J A Ajani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2018
Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapyC E McCoach, G M Blumenthal, L Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analogM E Royce, P M Hoff, P Dumas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemiaP F Bross, J Beitz, G Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1998
Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagusD H Ilson, J Ajani, K Bhalla, et al.
Cancer|October 15, 1992
Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinomaR Pazdur, J J Ajani, J L Abbruzzese, et al.
The Oncologist|February 13, 2001
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexaroteneM H Cohen, S Hirschfeld, S Flamm Honig, et al.
Pageof 16

Showing results (121-130 of 151) with videos related to

Sort By:
Pageof 16
Journal of the National Cancer Institute|December 12, 1992
Phase I trial of Taxotere: five-day scheduleR Pazdur, R A Newman, B M Newman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2019
Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancerG M Blumenthal, Y Gong, K Kehl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1994
Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinomaR Pazdur, Y Lassere, L T Soh, et al.
American Journal of Clinical Oncology|December 1, 1992
Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancerK P Hubbard, R Pazdur, J A Ajani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2018
Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapyC E McCoach, G M Blumenthal, L Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analogM E Royce, P M Hoff, P Dumas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemiaP F Bross, J Beitz, G Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1998
Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagusD H Ilson, J Ajani, K Bhalla, et al.
Cancer|October 15, 1992
Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinomaR Pazdur, J J Ajani, J L Abbruzzese, et al.
The Oncologist|February 13, 2001
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexaroteneM H Cohen, S Hirschfeld, S Flamm Honig, et al.
Pageof 16